When multiple myeloma relapses
RESPOND with higher response rates with Kyprolis®-based regimens (vs Vd)
Kd overall response rate
In the ENDEAVOR trial, more than half of patients achieved at least VGPR with Kd.1
Kyprolis®-based regimens consistently provided benefit to relapsed multiple myeloma patients, across different measures of response1
Kyprolis® has a tolerable safety profile in combination with dexamethasone
*Descriptive P value.
Please read the SmPC for full comprehensive safety information
- Dimopoulos MA et al. Lancet Oncol 2016;17:27–38.